Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1487751798
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
200 UCLA Medical Plz Ste 140
Los Angeles, CA, 90095
Phone (310) 794-7152
Groups this clinician bills Medicare through
Medicare paid, 2024
$128K
1,645 services
Medicare patients, 2024
160
Average age 77
Drug cost, 2024
$7.3M
956 prescriptions
Company payments, 2025
$51K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew Rettig was code J9217 (leuprolide acetate (for depot suspension), 7.5 mg), 379 times for 46 patients. In total Matthew Rettig billed 1,645 services in 13 codes, and Medicare paid $128K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-01-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 379 | 46 | $140.86 | $53K |
| 99214 Office E&M - Established | Office | 324 | 124 | $107.90 | $35K |
| 99213 Office E&M - Established | Office | 152 | 88 | $75.90 | $12K |
| 96402 Chemotherapy Administration | Office | 87 | 44 | $30.90 | $2,689 |
| 99215 Office E&M - Established | Office | 46 | 33 | $142.53 | $6,556 |
| 99205 Office E&M - New | Office | 30 | 30 | $179.11 | $5,373 |
| 96372 Injection Administration | Office | 19 | 16 | $11.54 | $219 |
By year: 2022 $140K for 1,270 services; 2023 $119K for 1,507 services; 2024 $128K for 1,645 services.
Medicare prescription drug claims, 2024
In 2024, the drug Matthew Rettig prescribed most often to Medicare patients was Nubeqa (Darolutamide), with 220 prescriptions and refills. In total Matthew Rettig wrote 956 Medicare prescriptions that cost $7.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Nubeqa Darolutamide | 220 | 220 | 27 | $3.0M |
| Xtandi Enzalutamide | 161 | 161 | 22 | $2.2M |
| Orgovyx Relugolix | 125 | 125 | 19 | $338K |
| Erleada Apalutamide | 97 | 97 | 12 | $1.4M |
| Abiraterone Acetate Generic | 94 | 129 | 17 | $194K |
| Prednisone Generic | 61 | 163 | 24 | $674 |
| Ibandronate Sodium Generic | 49 | 145 | 19 | $2,345 |
| Megestrol Acetate Generic | 22 | 61 | Under 11 | $1,140 |
| Tamsulosin Hcl Generic | 19 | 49 | Under 11 | $444 |
| Zytiga Abiraterone Acetate | 12 | 12 | Under 11 | $135K |
Brand drugs: 624 claims; generic drugs: 332 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew Rettig $51K ($51K in general payments such as food, travel and fees) from 10 companies. The largest payer was Bayer Healthcare Pharmaceuticals Inc. with $28K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.